INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

NCT03838042 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

91

Enrollment

OTHER

Sponsor class

Conditions

CNS Tumor
Solid Tumor

Interventions

DRUG: Nivolumab and Entinostat

Sponsor

University Hospital Heidelberg

Collaborators

[object Object]